Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [3][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [4][5]. - The report highlights that the November sales in the cosmetics sector were impacted by pre-Double 11 promotions and the rise of Douyin as a sales channel, leading to a weaker overall GMV [4][10]. - The collagen medical beauty segment is expanding, with two new animal-sourced collagen products approved for market, indicating growth potential in this area [4][10]. - The report emphasizes the strong market position of Mandi International in the minoxidil hair growth market, with a revenue increase from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% [4][11][12]. - L'Oréal's recent acquisition of an additional 10% stake in Galderma signifies a strategic shift towards medical aesthetics and skin health, aiming to adapt to the slowing growth in the Chinese beauty market [4][21]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 1.6%, with the Shenwan Cosmetics Index down by 1.2% and the Shenwan Personal Care Index down by 1.7% during the specified period [4][5]. - Notable stock performances included Water Sheep Co. (+5.9%) and Jinsong New Materials (+4.3%), while Hongmian Co. (-10.6%) and Juzhi Biological (-8.4%) faced significant declines [7]. Market Trends - The overall GMV for cosmetics in November was weak, influenced by the earlier sales surge in October and the emergence of Douyin as a competitive sales platform [4][10]. - The report notes that brands like Han Shu and Lin Qingxuan maintained stable GMV, while brands like Feicui continued to experience high growth [4][10]. Company Highlights - Mandi International has established a leading position in the minoxidil market, with a market share of approximately 57% in the hair loss treatment sector and 71% in the minoxidil product market as of 2024 [4][15]. - The company has shown consistent revenue growth, with a net profit increase from 2022 to the first half of 2025, indicating a robust business model [4][12][15]. Investment Recommendations - The report recommends focusing on companies with strong product lines and high profitability in the medical beauty sector, such as Ai Meike, while also suggesting attention to companies like Langzi Co. and Ru Yi Chen [4][10].

Company Overview - Company is a leading professional consumer healthcare platform in China, focusing on comprehensive and long-term skin health and weight management solutions, with its core brand "Mandi" dominating the minoxidil market in China, holding a market share of 70.6% in 2024 [1][2][14] - The company has a strong foundation in hair loss treatment and is actively expanding into broader skin health and weight management sectors [1][6] Shareholding Structure and Development History - The listing is a spin-off of high-quality assets within the Three Life Pharmaceutical system, ensuring a stable and strong shareholder background [2][24] - The company was established in 1997 and was the first in China to obtain approval for a 5% minoxidil solution in 2001, filling a market gap [2][24] - After being acquired by Three Life Pharmaceutical in 2015, the company entered a rapid growth phase, with Three Life remaining the controlling shareholder [2][24] Business Layout - The company has established a clear business matrix covering hair, skin, and weight management, with hair health being the cornerstone of its operations [6][26] - The hair health segment contributes the majority of revenue, while the company is also expanding into skin health with products like "Lai Zi" for atopic dermatitis and the acne treatment "Kela Tlong" [6][26] - In weight management, the company is preparing to launch the semaglutide injection, targeting a market projected to be worth hundreds of billions [6][26] Financial Analysis - The company has experienced rapid revenue growth, with revenue projected to increase from RMB 982 million in 2022 to RMB 1.455 billion in 2024, representing a CAGR of 21.7% [7][27] - The Mandi product line is the primary revenue driver, expected to generate RMB 1.327 billion in 2024, accounting for 92.1% of total revenue [7][27] - The company maintains strong profitability, with net profit expected to rise from RMB 202 million in 2022 to RMB 390 million in 2024, a CAGR of 38.9% [7][28] Industry Overview - The hair loss treatment market in China is substantial, with over 339 million individuals affected by hair loss, primarily androgenetic alopecia (AGA), which accounts for 90% of cases [9][30][31] - The market for hair health management is projected to grow from RMB 52.7 billion in 2024 to RMB 171.4 billion by 2035, with a CAGR of 11.3% [9][30] - Minoxidil is recognized as the gold standard for hair loss treatment, with its market share expected to increase from 80% to 82.2% between 2024 and 2035 [10][32] Acne Treatment Market - The acne treatment market is also significant, with over 121.2 million patients in China, expected to grow to 131.6 million by 2035 [15][36] - The market for acne treatment drugs is projected to increase from RMB 5 billion in 2024 to RMB 7.1 billion by 2035 [15][36] - The company has secured exclusive rights to the first topical androgen receptor inhibitor, Kela Tlong, which is expected to fill a gap in the market [15][38] Weight Management Market - The weight management market in China is poised for explosive growth, with the number of overweight and obese individuals projected to rise from 277.4 million in 2024 to 342.2 million by 2035 [17][39] - The market for weight loss drugs is expected to grow from RMB 2.3 billion in 2024 to RMB 80.4 billion by 2035, with a CAGR of 37.9% [17][39] - The company is advancing its semaglutide injection, which is expected to become one of the first domestically approved weight management products in China [17][42]

Core Insights - The nutrition and health supplement market is undergoing profound structural changes, necessitating continuous innovation for companies to achieve differentiated competition in an increasingly competitive environment [1][2] Industry Trends - The vitamin and mineral supplement industry is influenced by three long-term structural trends: 1. Accelerating population aging leading to upgraded demand, with elderly consumers seeking tailored nutritional solutions rather than generic products [1] 2. Significant changes in channel structure, with online consumption becoming an irreversible trend, particularly through e-commerce platforms [1][2] 3. The rise of younger consumer groups who prioritize novelty and experience in health products, requiring companies to innovate in product form, marketing, and brand communication [2] Company Strategy - The company has adopted a "Four New" strategy focusing on new products, new projects, new models, and new businesses, integrating this approach throughout its operations [2] - The vitamin product line has expanded from a single product to over 50 SKUs, catering to diverse demographic needs [2] - The company has made significant investments in social and interest e-commerce to enhance online and offline integration [2] Innovation Practices - Differentiation in the vitamin sector is achieved through segmentation and contextualization, enhancing product functionality and user perception [3] - The company emphasizes packaging and positioning innovation, as seen in its smoking cessation product, which aims to reduce the perception of being a pharmaceutical product [3] - In the probiotics sector, the company focuses on functional strains rather than engaging in price wars, establishing competitive barriers through proprietary strains [4] Collaboration and Precision Nutrition - The company collaborates with leading health check institutions to leverage health data for personalized probiotic formulations, allowing for higher pricing while maintaining sales growth [4] - The company believes that innovation is crucial not only for pharmaceutical companies but also in the OTC and health supplement sectors, aiming to meet consumer needs and achieve market recognition [4] Mission Statement - The company's mission is to serve the quality of life for consumers, focusing on health and lifestyle improvements through continuous innovation in its product offerings [4]

Group 1 - The core viewpoint is that the demand for consumer healthcare is expected to increase in the near future, along with the market space [2] - Companies need to focus on innovation to seize the opportunities presented by this market growth [2]

今年以来，医药生物板块整体保持稳健运行，防御性与增长韧性凸显，板块内部细分领域的分化特征愈 发明显。日前，财信证券研究发展中心医药生物行业首席分析师吴号表示，在政策支持升级与行业转型 深化的双重推动下，医药生物行业已全面迈入创新驱动的高质量发展阶段，"鼓励创新+成本控制"的政 策导向进一步塑造行业格局。随着行业基本面逐步修复，创新药、CXO、消费医疗三大投资主线的性 价比持续凸显，而AI等新技术与产业的深度融合，更开辟了全新增长空间，行业长期发展逻辑清晰， 投资价值逐步释放。（中证网） ...

Investment Rating - The report does not explicitly state an investment rating for the ophthalmology industry Core Insights - The ophthalmology medical service market in China is experiencing stable growth, with the market size projected to reach CNY 2,521.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 16.0% from 2020 to 2025 [7][10] - The revenue structure of companies in the industry is diversifying, with a notable increase in the proportion of refractive and optical services, while the basic medical sector faces pressure from policy changes and demand structure [3][50] - The overall growth rate of ophthalmology hospitals is slowing, with private hospitals expected to increase to 3,044 by 2028, while public hospitals will only expand to 83 [10][11] Company Summaries - Aier Eye Hospital continues to lead the industry with a revenue of CNY 174.84 billion, showing a 7.3% year-on-year growth, demonstrating strong risk resistance [25][29] - Huaxia Eye Hospital reported a revenue of CNY 32.7 billion, with a slight increase of 2.8% year-on-year, while its net profit rose by 3% to CNY 4.3 billion [25][26] - Puri Eye Hospital achieved a revenue of CNY 22.01 billion, with a 3.0% increase, but its net profit saw a significant drop of 66.1% due to new hospital losses and high expenses [25][30] - He Eye Hospital's revenue decreased by 1.1% to CNY 8.6 billion, but its net profit surged by 232.2% to CNY 0.54 billion, benefiting from regional business optimization [25][30] - Xima Medical reported a revenue of CNY 8.6 billion in 2025H1, a 61.29% increase year-on-year, achieving breakeven in mainland China operations [41][41] Market Dynamics - The proportion of refractive income is increasing across companies, with Puri Eye Hospital leading at 49.34%, followed by Aier Eye Hospital at 40.13% [50][47] - The cataract income share is declining, particularly for Huaxia Eye Hospital, which dropped from 22.70% to 20.15% due to the impact of centralized procurement policies [50][51] - The report highlights a trend of increasing high-end surgical procedures, which is driving up average transaction prices in the industry [58]

Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 5.5 yuan, compared to the current price of 4.79 yuan [3][7]. Core Insights - The company reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%. The net profit attributable to the parent company was a loss of 294 million yuan, with a year-on-year increase in losses of 38.45% [2][7]. - The decline in revenue is attributed to two main factors: adjustments in medical insurance payment policies leading to a decrease in inpatient service volume and the ongoing reform of the DRG payment method, which has reduced the average cost per inpatient [7]. - Despite the short-term pressure on revenue, the company has seen a steady increase in outpatient and emergency services, with a total of 1.9751 million visits, a year-on-year increase of 4.03% [7]. - The company is focusing on strategic growth areas, including high-barrier projects like the proton therapy center, consumer healthcare, and data assetization, which are expected to enhance long-term competitiveness [7]. Financial Summary - For 2025, the company is projected to have total revenue of 4.055 billion yuan, a decrease of 15.8% year-on-year, with a net profit attributable to the parent company expected to be a loss of 343 million yuan [2][8]. - The company’s financial metrics indicate a projected net profit growth rate of 74.5% in 2026 and 214.8% in 2027, suggesting a potential recovery in profitability [8]. - The company’s total assets are estimated to be 10.422 billion yuan in 2025, with a debt-to-equity ratio of 164.2% [8].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 Mandi Inc. 蔓迪國際 （於開曼群島註冊成立的有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊發， 僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知悉、 接納並向Mandi Inc.（蔓迪国际）（「本公司」）、其獨家保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章 公 司（清 盤 及 雜 項 條 文）條 例 送 呈 香 港 公 司 註 冊 處 處 長 登 記 前，本 公 司 不 會 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請。倘 於 適 當 時 候 向 香 港 公 眾 人 士 提 出 要 約 或 邀 請，有 意 投 資 者 務 請 僅 依 據 呈 交 香港公司註冊處處長註冊的本公司 ...

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare sector [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in areas such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]

Core Viewpoint - Betta Pharmaceuticals (300957.SZ) aims to enhance its comprehensive competitiveness and profitability by becoming a limited partner in a new investment fund focused on the healthcare industry [1] Group 1: Investment Details - The company will invest 50 million yuan as a limited partner in the Wuxi Jinyu Maowu Medical Health Industry Investment Partnership, holding a 5% share in the fund [1] - The fund is established in collaboration with several partners, including Wuxi Jinjiao Investment Partnership and Jiangsu Wuxi Biomedical Industry Special Mother Fund [1] Group 2: Investment Focus - The partnership will primarily invest in sectors such as consumer healthcare, quality improvement of national health, pharmaceuticals (including synthetic biology and innovative drugs), medical devices, supportive medical industries, and AI-driven pharmaceuticals [1]